Senior Vice President, Business Development

Mr. Goyal brings more than 15 years of experience in business strategy, financing and business development for biotechnology companies. Most recently, he served as a Principal of SR One, the corporate venture capital arm of GlaxoSmithKline, where he invested in multiple autoimmune disease focused companies including Morphic Therapeutics (Nasdaq: MORF), River Vision Development (acquired by Horizon), and Pandion. Mr. Goyal is a member of the Board of Directors of Morphic Therapeutics. Previously, Mr. Goyal was a Consultant at McKinsey & Co, a co-founder of Extera Partners and a Business Development Manager at Infinity Pharmaceuticals. He is a member of the Kauffman Fellows Society. Mr. Goyal earned an MBA in Health Care Management from the Wharton School of the University of Pennsylvania and a BA in neurobiology from Harvard University.